Silica Corpora is a Drug Discovery company which aims to develop tailored AI-solutions to develop more-quality and more cost-effective antibody therapeutics. The estimated cost of bringing a new prescription drug to the market has risen dramatically from $1.1B in 2003 to $2.3B in 2019 while early stages of drug discovery take around 3 years. Artificial Intelligence (AI) approaches have the potential to improve drug discovery by making it faster, optimizing the cost, and making the drugs more quality and effective. The replacement of lead generation and lead optimization stages of antibody drug discovery with AI may reduce the times and costs of early antibody discovery by 10-100 times.